In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Plant-based artificial Christmas trees set to launch this December
In California, artificial Christmas tree maker Balsam Brands will launch a new line of trees for 2025’s holiday season that use needles made of...
Artist Sam Shoemaker takes mushroom kayak on twelve-hour journey
In California, an artist and “mycologist” has crossed 26 miles of ocean in a kayak made of mycelium, the root system of mushrooms.
Sam...
Canadian funeral group becomes first to offer Loop’s mycelium coffins and urns
In Canada, Mount Pleasant Group’s Meadowvale Cemetery, Funeral and Cremation Centres have become the first in Canada to offer the Loop Living Cocoon and...